Catalent (NYSE:CTLT) shares dipped today despite first-quarter financial results that beat the consensus forecast.
The Somerset, New Jersey-based company posted profits of $93 million, or 49¢ per share, on sales of $1.025 billion for the three months ended Sept. 30, 2021, for a 13.4% bottom-line gain on sales growth of 21.2%.
Get the full story at our sister site, Drug Delivery Business News.
